Down-Regulation of Bcl-2 Is a Potential Marker of the Efficacy of Progestin Therapy in the Treatment of Endometrial Hyperplasia

This publication has 28 references indexed in Scilit:

• Expression of Bcl-2 and Bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis
  British Journal of Dermatology, 1997
• bcl-2 Expression in Endometrial Hyperplasia and Carcinoma
  Gynecologic Oncology, 1996
• Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells
  International Journal of Cancer, 1996
• Immunohistochemical Analysis of Endometrial Adenocarcinoma for bcl-2 and p53 in Relation to Expression of Sex Steroid Receptor and Proliferative Activity
  International Journal of Gynecological Pathology, 1996
• Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity
  International Journal of Gynecologic Cancer, 1996
• Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle
  The Lancet, 1994
• Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor
  Cancer Letters, 1992
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
  Nature, 1990
• Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy
  International Journal of Cancer, 1979
• Progestin therapy in endometrial hyperplasia
  Gynecologic Oncology, 1974